[an error occurred while processing this directive] | [an error occurred while processing this directive]
The application of whole-brain radiotherapy for non-small cell lung cancer with brain metastases:evolution and revolution
Yang Siran, Xiao Jianping
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021,China
Abstract Whole brain radiotherapy (WBRT) was widely used clinically as the standard therapy for brain metastases (BM). With the development of radiotherapy technology and systemic therapies,the non-small cell lung cancer (NSCLC) patients have prolonged local control rate and median survival time,meanwhile post-radiotherapy intracranial toxicities often lead to serious impacts on the quality of life and neurocognitive function. Therefore,the role WBRT played should have been reevaluated. The purpose of this review is to analyze the clinical application value of WBRT in the context of new treatments for NSCLC with BM,and to predict the main developing directions of WBRT in the future.
Yang Siran,Xiao Jianping. The application of whole-brain radiotherapy for non-small cell lung cancer with brain metastases:evolution and revolution[J]. Chinese Journal of Radiation Oncology, 2019, 28(10): 784-791.
Yang Siran,Xiao Jianping. The application of whole-brain radiotherapy for non-small cell lung cancer with brain metastases:evolution and revolution[J]. Chinese Journal of Radiation Oncology, 2019, 28(10): 784-791.
[1] Andratschke N,Kraft J,Nieder C,et al. Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC)[J]. Lung Cancer,2019,129:63-71. DOI:10.1016/j.lungcan.2018.12.009. [2] Li J,Bentzen SM,Renschler M,et al. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function[J]. J Clin Oncol,2007,25(10):1260-1266. DOI:10.1200/jco.2006.09.2536. [3] Mulvenna P,Nankivell M,Barton R,et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ):results from a phase 3,non-inferiority,randomised trial[J]. Lancet,2016,388(10055):2004-2014. DOI:10.1016/s0140-6736(16)30825-x. [4] Mahajan A,Ahmed S,Mcaleer MF,et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases:a single-centre,randomised,controlled,phase 3 trial[J]. Lancet Oncol,2017,18(8):1040-1048. DOI:10.1016/s1470-2045(17)30414-x. [5] Kocher M,Soffietti R,Abacioglu U,et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases:results of the EORTC 22952-26001 study[J]. J Clin Oncol,2011,29(2):134-141. DOI:10.1200/jco.2010.30.1655. [6] Brown PD,Ballman KV,Cerhan JH,et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3):a multicentre,randomised,controlled,phase 3 trial[J]. Lancet Oncol,2017,18(8):1049-1060. DOI:10.1016/s1470-2045(17)30441-2. [7] Kayama T,Sato S,Sakurada K,et al. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504):a phase Ⅲ,noninferiority,randomized controlled trial[J]. J Clin Oncol,2018,33(36):3282-3289. DOI:10.1200/jco.2018.78.6186.36. [8] Yamamoto M,Serizawa T,Higuchi Y,et al. A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 study update):irradiation-related complications and long-term maintenance of mini-mental state examination scores[J]. Int J Radiat Oncol Biol Phys,2017,99(1):31-40. DOI:10.1016/j.ijrobp.2017.04.037. [9] Sahgal A,Aoyama H,Kocher M,et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases:individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys,2015,91(4):710-717. DOI:10.1016/j.ijrobp.2014.10.024. [10] Aoyama H,Tago M,Shirato H,et al. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases:secondary analysis of the JROSG 99-1 randomized clinical trial[J]. JAMA Oncol,2015,1(4):457-464. DOI:10.1001/jamaoncol.2015.1145. [11] Brown PD,Jaeckle K,Ballman KV,et al. Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases:a randomized clinical trial[J]. JAMA,2016,316(4):401-449. DOI:10.1001/jama.2016.9839. [12] Churilla TM,Ballman KV,Brown PD,et al. Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases:a secondary analysis of the north central cancer treatment group N0574(Alliance) randomized controlled trial[J]. Int J Radiat Oncol Biol Phys,2017,99(5):1173-1178. DOI:10.1016/j.ijrobp.2017.07.045. [13] Robin TP,Camidge DR,Stuhr K,et al. Excellent outcomes with radiosurgery for multiple brain metastases in ALK and EGFR driven non-small cell lung cancer[J]. J Thorac Oncol,2018,13(5):715-720. DOI:10.1016/j.jtho.2017.12.006 [14] Wu YL,Zhao Q,Deng L,et al. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer[J]. Lung Cancer,2019,127:1-5. DOI:10.1016/j.lungcan.2018.11.022. [15] Farris M,Mctyre ER,Cramer CK,et al. Brain metastasis velocity:a novel prognostic metric predictive of overall survival and freedom from whole-brain radiation therapy after distant brain failure following upfront radiosurgery alone[J]. Int J Radiat Oncol Biol Phys,2017,98(1):131-141. DOI:10.1016/j.ijrobp.2017.01.201. [16] 马玉超,肖建平,毕楠,等. HT全脑+病灶同步推量放疗多发性脑转移瘤剂量学及临床分析[J]. 中华放射肿瘤学杂志,2018,27(5):435-440. Ma YC,Xiao JP,Bi N,et al. Dosimetry and clinical analysis of HT whole brain+focus simultaneous integrated boost radiotherapy for multiple brain metastases[J]. Chin J Radiat Oncol,2018,27(5):435-440. DOI:10.3760/cma.j.issn.1004-4221.2018.05.001. [17] Gore EM,Bae K,Wong SJ,et al. Phase Ⅲ comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer:primary analysis of radiation therapy oncology group study RTOG 0214[J]. J Clin Oncol,2011,29(3):272-278. DOI:10.1200/jco.2010.29.1609. [18] De Ruysscher D,Dingemans AC,Praag J,et al. Prophylactic cranial irradiation versus observation in radically treated stage Ⅲ non-small-cell lung cancer:a randomized phase Ⅲ NVALT-11/DLCRG-02 study[J]. J Clin Oncol,2018,36(23):2366-2377. DOI:10.1200/jco.2017.77.5817. [19] Brown PD,Pugh S,Laack NN,et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy:a randomized, double-blind,placebo-controlled trial[J]. Neuro Oncol,2013,15(10):1429-1437. DOI:10.1093/neuonc/not114. [20] Gondi V,Pugh SL,Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933):a phase Ⅱ multi-institutional trial[J]. J Clin Oncol,2014,32(34):3810-3816. DOI:10.1200/jco.2014.57.2909. [21] Kim Y,Kim SH,Lee JH,et al. Verification of low risk for perihippocampal recurrence in patients with brain metastases who received whole-brain radiotherapy with hippocampal avoidance[J]. Cancer Res Treat,2019,51(2):568-575. DOI:10.4143/crt.2018.206. [22] Inno A, Di Noia V, D′argento E,et al. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer[J]. Transl Lung Cancer Res,2016,5(6):599-609. DOI:10.21037/tlcr.2016.11.01 [23] Sperduto PW,Yang TJ,Beal K,et al. The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases[J]. Int J Radiat Oncol Biol Phys,2016,96(2):406-413. DOI:10.1016/j.ijrobp.2016.06.006. [24] Mok TS,Wu YL,Ahn MJ,et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med,2017,376(7):629-640. DOI:10.1056/nejmoa1612674. [25] Yang J-J,Zhou C,Huang Y,et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN):a multicentre,phase 3,open-label,parallel,randomised controlled trial[J]. Lancet Respirat Med,2017,5(9):707-716. DOI:10.1016/s2213-2600(17)30262-x. [26] Magnuson WJ,Lester-Coll NH,Wu AJ,et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer:a retrospective multi-institutional analysis[J]. J Clin Oncol,2017,35(10):1070-1077. DOI:10.1200/jco.2016.69.7144. [27] Jiang T,Su C,Li X,et al. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases[J]. J Thorac Oncol,2016,11(10):1718-1728. DOI:10.1016/j.jtho.2016.05.013. [28] Camidge DR,Kim HR,Ahn MJ,et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer[J]. N Engl J Med,2018,379(21):2027-2039. DOI:10.1056/nejmoa1810171. [29] Kim DW,Tiseo M,Ahn MJ,et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer:a randomized, multicenter phase Ⅱ trial[J]. J Clin Oncol,2017,35(22):2490-2498. DOI:10.1200/jco.2016.71.5904 [30] Johung KL,Yeh N,Desai NB,et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis[J]. J Clin Oncol,2016,34(2):123-129. DOI:10.1200/jco.2015.62.0138. [31] Gadgeel S,Peters S,Mok T,et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer:CNS efficacy results from the ALEX study[J]. Ann Oncol,2018,29(11):2214-22. DOI:10.1200/jco.2015.62.0138. [32] Goldberg SB,Gettinger SN,Mahajan A,et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised,open-label,phase 2 trial[J]. Lancet Oncol,2016,17(7):976-983. DOI:10.1016/s1470-2045(16)30053-5. [33] Tawbi HA,Forsyth PA,Algazi A,et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain[J]. N Engl J Med,2018,379(8):722-730. DOI:10.1056/nejmoa1805453. [34] Colaco RJ,Martin P,Kluger HM,et al. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?[J]. J Neurosurg,2016,125(1):17-23. DOI:10.3171/2015.6.jns142763.
2019, Vol. 28 
